Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma

Prospective HOVON-902 cohort, curative-intent first-line treatment. Phased-variant identification successful in 134 of 136 (99%). At end of treatment, 83% were MRD-negative and 17% MRD-positive. 3-year PFS 17% vs 85% (HR 9.8, 95% CI 5.1-19, P=9.63×10^-12); OS 43% vs 92% (HR 7.7, 95% CI 3.4-17.4, P=1.27×10^-6). MRD positivity had higher PPV for 2-year PFS than positive PET (68% vs 56%, P≤.001); NPV similar (89% vs 88%). This is not a POLARIX analysis. Level 2.

J Clin OncolPubMed 41385760